6-fluoroprostaglandins
AssigneesAsahi Glass Company, Limited, Dainippon Pharmaceutical Co., Ltd.
InventorsNaonobu Hatano, Buichi Fujitani, Toshiaki Kadokawa, Yasushi Matsumura, Tomoyuki Asai, Arata Yasuda, Keiichi Uchida
Life of this patent
Estimating the term…
Abstract
A 6-fluoroprostaglandin having the formula: ##STR1## wherein A is a carbonyl group or a hydroxymethylene group, R.sup.1 is a substituted or unsubstituted C.sub.1 -C.sub.10 alkyl group or a substituted or unsubstituted 5- or 6-membered cycloalkyl group, R.sup.2 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group, each of R.sup.3 and R.sup.4 which may be the same or different is a hydrogen atom or a protecting group, R.sup.5 is a hydrogen atom or a hydroxyl group, and is a single bond or a double bond, and its salt when R.sup.2 is a hydrogen atom.
Claims8
A 6-fluoroprostaglandin having the formula:
- ##STR24## wherein A is a carbonyl group or a hydroxymethylene group, R.sup.1 is a straight chain or branched C.sub.4 -C.sub.8 alkyl group, R.sup.2 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group, each of R.sup.3 and R.sup.4, which may be the same or different, is a hydrogen atom or a protecting group, R.sup.5 is a hydrogen atom or a hydroxyl group, and is a single bond or a double bond, and its salt when R.sup.2 is a hydrogen atom.
A drug composition having an antiplatelet effect, an antianginal effect or an inhibitory effect on gastric ulcers, which comprises:
- a therapeutically effective amount of a 6-fluoroprostaglandin compound having the formula:
- ##STR25## wherein A is a carbonyl group or a hydroxymethylene group, R.sup.1 is a straight chain or branched C.sub.4 -C.sub.8 alkyl group, R.sup.2 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group, and represents a single bond or a double bond, or its salt, on a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.